Physician profile
Jodi Killilea
NPI 1235647066
$854.97
in general payments reported to CMS, 2019-2025
15 companies · $503 in 2025
The $503 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $243 · 2024: $108 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $854.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $184.32 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $125.00 | 2023 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $118.19 | 2023 | Austedo Xr |
| Aimmune Therapeutics, INC. | $60.10 | 2025 | Zenpep |
| Astrazeneca Pharmaceuticals LP | $53.18 | 2025 | Farxiga |
| Amgen INC. | $44.66 | 2025 | Repatha, Otezla |
| Novo Nordisk INC | $44.34 | 2025 | Wegovy, Ozempic |
| Viiv Healthcare Company | $37.67 | 2025 | Apretude |
| Astellas Pharma US INC | $37.58 | 2025 | Veozah |
| Glaxosmithkline, LLC. | $37.52 | 2025 | Shingrix, Arexvy |
| Dexcom, INC. | $28.86 | 2025 | Dexcom G6 Transmitter |
| Seqirus USA INC | $25.09 | 2025 | Fluad, Flucelvax |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.01 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $17.56 | 2025 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $15.89 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodi Killilea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.